![Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/9e2160f1-f0ab-460d-b6f2-54ba0a214318/gr1.gif)
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial - The Lancet HIV
![Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens](https://www.natap.org/2010/images/041510/041510-6/image002.gif)
Ritonavir boosting of low-dose danoprevir (RG7227; ITMN-191), HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens
![Antiretroviral boosting by cobicistat, a structural analog of ritonavir - Greenblatt - 2014 - Clinical Pharmacology in Drug Development - Wiley Online Library Antiretroviral boosting by cobicistat, a structural analog of ritonavir - Greenblatt - 2014 - Clinical Pharmacology in Drug Development - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/62314dee-7440-4828-b3ae-bc74bcad79c9/cpdd159-fig-0001-m.jpg)
Antiretroviral boosting by cobicistat, a structural analog of ritonavir - Greenblatt - 2014 - Clinical Pharmacology in Drug Development - Wiley Online Library
![HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal](https://www.ahajournals.org/cms/asset/d9b9ed03-620a-4999-938a-478bf7b161e6/jah35534-fig-0007.png)
HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal
![Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/ddi/2020/lopinavir-ritonavir.jpg)
Experimental COVID-19 Therapy Combination Lopinavir/Ritonavir Is Implicated in a Complicated Set of Drug-Drug Interactions - Anesthesia Patient Safety Foundation
![PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7d953a0329d21331a2a46a14d7aafc1acda29ab6/2-Table1-1.png)
PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar
![Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat](https://pub.mdpi-res.com/biomedicines/biomedicines-09-00313/article_deploy/html/images/biomedicines-09-00313-ag.png?1617783328)
Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
![The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223004249-gr1.jpg)